MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients
Recruiting
N/A
Interventional Study
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 55
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 200 (estimated)
- Sponsor
- National Research Center for Hematology, Russia · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Non-intensive But Non-interruptive Treatment based on previously study RALL-2016 of Adult Ph-negative Acute Lymphoblastic Leukemia: No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks, L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, T-ALL patients in complete remission (CR) with MRD-positive status after 2n…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
• age 18-55 years old of patient,
\- Clinical diagnosis of non-treated Ph-negative ALL
Exclusion Criteria:
• age more than 55 years old,
* Clinical diagnosis of Ph-positive ALL
* Clinical diagnosis of relapsed/refractory ALL,
Contacts